drugset / Trial / NCT05666804
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor (VEGF) treatment.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2025-09-10
- Completion
- 2025-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brolucizumab | Other / unclassified | 6 mg | Intravitreal |
Indications
No indication recorded.